Latest Conference Articles

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Fruquintinib Plus TAS-102 Demonstrates Efficacy and Acceptable Toxicity in Pretreated mCRC

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.

Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Nivolumab Plus Ipilimumab Prolongs PFS vs Nivolumab Alone in MSI-H/dMMR mCRC

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets

The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.

Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer

Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

Single-Cycle Neoadjuvant Pembrolizumab Is Efficacious, Safe in dMMR Colon Cancer

Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.

Trifluridine/Tipiracil Demonstrates DFS Benefit Over Placebo in Resected Stage IV CRC

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer

The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.

Dose Reductions of Liposomal Irinotecan, Oxaliplatin Are Not Associated With Worsened OS in Metastatic PDAC

NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.

First-Line FOLFIRINOX Fails to Improve OS vs First-Line NALIRIFOX in Metastatic PDAC

The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.

Aspirin Is Associated With Reduced Recurrence Risk in PI3K+ CRC

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.

Addition of CRT to Chemotherapy Does Not Improve RFS in Resected Gallbladder Cancer

Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.

Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.

Pelareorep Plus mFOLFIRINOX ± Atezolizumab Shows Acceptable Safety in Metastatic PDAC

Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.

NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis

Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.